Keywords

• Silodosin
• 160970-54-7
• C25H32F3N3O4

Quick Details

• ProName: Silodosin160970-54-7
• CasNo: 160970-54-7
• Molecular Formula: C25H32F3N3O4
• Appearance: detailed in specifcations
• Application: Aripiprazole Intermediate functional...
• DeliveryTime: within 5days
• PackAge: as needed
• Port: China main port
• ProductionCapacity: 500 Metric Ton/Month
• Purity: 99%
• Storage: Keep in dry and cool condition
• Transportation: by air or sea
• LimitNum: 1 Kilogram
• MF: C13H21O3PS

Superiority

Our Services

1.Certificate Of Analysis (COA)

2.Material Safety Data Sheet (MSDS)

3.Route of synthesis (ROS)

4.Method of Aanlysis (MOA)

5.Nuclear Magnetic Resonance (NMR)

6.Packing pictures and loading video before loading

7.Free Sample

9.Factory audit

10.Strong after-sale service

Company information

Henan Sunlake Enterprise Corporation is located in Henan Province , The central plain of China , Which enjoys favorable geogeaphical position and convenient transportion, The com[any was established in june. 1998 , until now having more than 18 years experience in manufacturing & exporting chemical raw material .Sunlake is a professional manufacturer engaged in producing and selling chemicals,including Organic & inorganic chemicals , pigments & Dyestuffs , Water treatment chemicals , Food & FEED additives and others . these products have been being well exported to europe , southeast Asia , the Middle East , Africa , South America and some other countries and areas.We sincerely welcome foreign friends to visit our plant for cooperation. With the idea of "quality first,credit priority, Excellent service", We are highly acknowledged by customers for good quality and competitive price. More importantly , the company has a strong R & D team, who are professional engineers and scholars with Ph. D. .So we are confident to serve you better with our high - quality products and professional team.We are taking great efforts to provide our customers with demanded goods and professional services, and continuously improve our core ability of competition and get the momentum for sustainable development, and finally make us being a reliable and professional wupplier in international market.We welcome any serious inquiries from all customers of the world, and sincerely hope to cooperate.

Details

Silodosin Basic information

Treatment of prostatic hyperplasia Benign prostatic hyperplasia Application

Product Name:	Silodosin
Synonyms:	(–)-1-(3-Hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-2,3-di-hydro-1H-indole-7-carboxamide;Silodosin;KAD 3213;KMD 3213;Urief;Silodosin API;Silodosin(Rapaflo);(–)-1-(3-Hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-tr
CAS:	160970-54-7
MF:	C25H32F3N3O4
MW:	495.53
EINECS:
Product Categories:	Amines;Aromatics;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;KAD 3213, KMD 3213;Other APIs
Mol File:	160970-54-7.mol

Silodosin Chemical Properties

CAS DataBase Reference

160970-54-7(CAS DataBase Reference)

Safety Information

MSDS Information

 

Silodosin Usage And Synthesis

Treatment of prostatic hyperplasia

Silodosin is a kind of α- adrenergic receptor antagonists developed by Japanese Kissei pharmaceutical company. It has a very good therapeutic efficacy on treating the dysuria related to benign prostatic hyperplasia. The selective effect on urethra of Silodosin is 12 times and 7.4 times as high as that of prazosin and tamsulosin, respectively, which can significantly inhibit norepinephrine-induced contraction of the prostate; it has dose-dependent inhibition bladder activity excitation in the benign prostatic hypertrophy models of rats, and can also improve the pressure threshold of bladder contraction. These data have suggested that, in addition to helping improve bladder function, silodosin is also effective in alleviating the related symptoms associated with benign prostatic hypertrophy. Compared with similar drugs such as prazosin and tamsulosin, silodosin has a high selectivity onn theα1A- receptors located in the prostate and bladder neck, while having a low affinity to theα1B- and α1D-receptor. It can block theα1A- receptors in these sites, and relax the smooth muscle, and thus leading to the improvement of urinary flow rate and the alleviation of BPH symptoms. The selective binding to the α1A-receptor by silodosin has a higher selectivity compared to the binding to the cardiovascular associated receptors α1B, thus maximizing the activity of the target organ as well as minimizing the potential effect on blood pressure. The above information is edited by the chemicalbook of Dai Xiongfeng.

Benign prostatic hyperplasia

Benign prostatic hyperplasia (referred as BPH) is one of the most common diseases in older male with the non-malignant prostate being the character. It can cause the obstructive urination symptoms and other irritation symptoms which have brought significant negative impact on the life of older people. In recent years, with the increasing